292 related articles for article (PubMed ID: 17875049)
21. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
Neukamm A; Høiseth AD; Einvik G; Lehmann S; Hagve TA; Søyseth V; Omland T
J Intern Med; 2015 Jul; 278(1):59-67. PubMed ID: 25495178
[TBL] [Abstract][Full Text] [Related]
22. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
Onishi K
J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523
[TBL] [Abstract][Full Text] [Related]
23. COPD and stroke: are systemic inflammation and oxidative stress the missing links?
Austin V; Crack PJ; Bozinovski S; Miller AA; Vlahos R
Clin Sci (Lond); 2016 Jul; 130(13):1039-50. PubMed ID: 27215677
[TBL] [Abstract][Full Text] [Related]
24. [COPD, a systemic disease!… or not?].
Burgel PR; Marchand E
Rev Mal Respir; 2010 Dec; 27(10):1128-9. PubMed ID: 21163390
[No Abstract] [Full Text] [Related]
25. Airflow obstruction was associated with elevation of brachial-ankle pulse wave velocity but not ankle-brachial index in aged patients with chronic obstructive pulmonary disease.
Chen R; He W; Zhang K; Zheng H; Lin L; Nie R; Wang J; Huang H
Atherosclerosis; 2015 Sep; 242(1):135-40. PubMed ID: 26188536
[TBL] [Abstract][Full Text] [Related]
26. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification.
Rennard SI
Proc Am Thorac Soc; 2006 May; 3(3):276-80. PubMed ID: 16636098
[TBL] [Abstract][Full Text] [Related]
27. Chronic obstructive pulmonary disease and comorbidity: a review and consideration of pathophysiology.
Tan SL; Wood AM
Panminerva Med; 2009 Jun; 51(2):81-93. PubMed ID: 19776710
[TBL] [Abstract][Full Text] [Related]
28. Undiagnosed airflow limitation in patients at cardiovascular risk.
Bérard E; Bongard V; Roche N; Perez T; Brouquières D; Taraszkiewicz D; Fievez S; Denis F; Escamilla R; Ferrières J
Arch Cardiovasc Dis; 2011 Dec; 104(12):619-26. PubMed ID: 22152514
[TBL] [Abstract][Full Text] [Related]
29. The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)--a review.
Lee PN
Regul Toxicol Pharmacol; 2013 Dec; 67(3):372-81. PubMed ID: 24013038
[TBL] [Abstract][Full Text] [Related]
30. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence.
Young RP; Hopkins R; Eaton TE
Postgrad Med J; 2009 Aug; 85(1006):414-21. PubMed ID: 19633007
[TBL] [Abstract][Full Text] [Related]
31. Neurohumoral activation as a link to systemic manifestations of chronic lung disease.
Andreas S; Anker SD; Scanlon PD; Somers VK
Chest; 2005 Nov; 128(5):3618-24. PubMed ID: 16304321
[TBL] [Abstract][Full Text] [Related]
32. Mortality in COPD: Role of comorbidities.
Sin DD; Anthonisen NR; Soriano JB; Agusti AG
Eur Respir J; 2006 Dec; 28(6):1245-57. PubMed ID: 17138679
[TBL] [Abstract][Full Text] [Related]
33. [Cell senescence and pathophysiology of chronic lung diseases: role in chronic obstructive pulmonary disease].
Adnot S
Bull Acad Natl Med; 2014; 198(4-5):659-71. PubMed ID: 26753399
[TBL] [Abstract][Full Text] [Related]
34. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease.
Bando M; Miyazawa T; Shinohara H; Owada T; Terakado M; Sugiyama Y
Respirology; 2012 Apr; 17(3):493-8. PubMed ID: 22142478
[TBL] [Abstract][Full Text] [Related]
35. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention.
Decramer M; Rennard S; Troosters T; Mapel DW; Giardino N; Mannino D; Wouters E; Sethi S; Cooper CB
COPD; 2008 Aug; 5(4):235-56. PubMed ID: 18671149
[TBL] [Abstract][Full Text] [Related]
36. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?
Stone IS; Barnes NC; Petersen SE
Heart; 2012 Jul; 98(14):1055-62. PubMed ID: 22739636
[TBL] [Abstract][Full Text] [Related]
37. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities.
Young RP; Hopkins RJ
Expert Rev Respir Med; 2013 Oct; 7(5):533-44. PubMed ID: 24138695
[TBL] [Abstract][Full Text] [Related]
38. Systemic manifestations of COPD.
Nussbaumer-Ochsner Y; Rabe KF
Chest; 2011 Jan; 139(1):165-73. PubMed ID: 21208876
[TBL] [Abstract][Full Text] [Related]
39. Myocardial perfusion reserve is impaired in patients with chronic obstructive pulmonary disease: a comparison to current smokers.
Nakamori S; Onishi K; Ishida M; Nakajima H; Yamada T; Nagata M; Kitagawa K; Dohi K; Nakamura M; Sakuma H; Ito M
Eur Heart J Cardiovasc Imaging; 2014 Feb; 15(2):180-8. PubMed ID: 23839654
[TBL] [Abstract][Full Text] [Related]
40. [Pleiotropic Effects of Rosuvastatin in Chronic Obstructive Pulmonary Disease Patients With High Cardiovascular Risk].
Samorukova EI; Adasheva TV; Zadionchenko VS; Rosliakova GA
Kardiologiia; 2015; 55(7):32-7. PubMed ID: 26688923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
